リスク保有患者におけるバリシチニブの安全性: リウマチおよび皮膚科領域の臨床試験解析
Adv Ther. 2023;40(4):1867–1883 doi: 10.1007/s12325-023-02445-w
Analysis of pooled data from the baricitinib clinical development programmes finds a low incidence rate of MACE, myocardial infarction, lung cancer, VTE, and overall mortality in patients <65 years without risk factors.
JAK inhibitors have been linked to a possible class effect associated with particular adverse events, such as MACE, VTE, and malignancy. As such, further characterisation of adverse events of special interest (AESIs) in at-risk populations will improve the risk-benefit assessment for individual patients and diseases. To help address this, Taylor, et al. expand on the safety of baricitinib for AESI, across all approved indications.
Keywords:
